Medicare Enrolled

Dr. Tatiana Nagibina, M.D.

Rheumatology · Palm Harbor, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
32615 US HIGHWAY 19 N, Palm Harbor, FL 34684
7277892784
In practice since 2006 (20 years)
NPI: 1003876756 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Nagibina from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nagibina? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Nagibina

Dr. Tatiana Nagibina is a rheumatology in Palm Harbor, FL, with 20 years in practice. Based on federal Medicare data, Dr. Nagibina performed 5,161 Medicare services across 404 unique beneficiaries.

Between the years covered by Open Payments, Dr. Nagibina received a total of $25,340 from 50 pharmaceutical and/or device companies across 1423 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Nagibina is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 50% volume in FL$ $25,340 industry payments

Medicare Practice Summary

Medicare Utilization ↗
5,161
Medicare services
Top 50% in FL for rheumatology
404
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~258 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)3,960$19$27
Office visit, established patient (30-39 min)401$91$170
Physical therapy exercise, per 15 min236$19$60
Manual therapy (hands-on treatment), per 15 min138$16$60
Administration of chemotherapy into vein, 1 hour or less97$96$260
Office visit, established patient (20-29 min)91$62$120
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle90$54$140
Bone density scan (DEXA)41$36$100
X-ray of wrist, minimum of 3 views22$31$85
X-ray of hand, minimum of 3 views22$28$70
Foot X-ray, 3+ views22$22$85
Chest X-ray, 2 views16$24$50
Office visit, established patient, complex (40-54 min)14$130$200
New patient office visit (45-59 min)11$100$300
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$25,340
Total received (2018-2024)
Avg $3,620/year across 7 years
Top 18% in FL for rheumatology
50
Companies
1,423
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$25,227 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$113 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,182
2023
$4,136
2022
$3,815
2021
$3,599
2020
$2,759
2019
$3,361
2018
$3,488

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$4,439
Novartis Pharmaceuticals Corporation
$1,913
PFIZER INC.
$1,724
UCB, Inc.
$1,555
GlaxoSmithKline, LLC.
$1,545
ABBVIE INC.
$1,424
E.R. Squibb & Sons, L.L.C.
$1,345
Janssen Biotech, Inc.
$1,227
Lilly USA, LLC
$1,164
Mallinckrodt Hospital Products Inc.
$1,076
GENZYME CORPORATION
$972
Radius Health, Inc.
$850
AbbVie Inc.
$833
Boehringer Ingelheim Pharmaceuticals, Inc.
$712
AbbVie, Inc.
$639
Horizon Therapeutics plc
$500
Genentech USA, Inc.
$432
AstraZeneca Pharmaceuticals LP
$367
Fresenius Kabi USA, LLC
$333
Horizon Pharma plc
$320
Sobi, Inc
$234
SOBI, INC
$218
Antares Pharma, Inc.
$215
Alexion Pharmaceuticals, Inc.
$139
Dexcom, Inc.
$124
Janssen Scientific Affairs, LLC
$124
Mallinckrodt Enterprises LLC
$123
United Therapeutics Corporation
$113
Aurinia Pharma U.S., Inc.
$92
Mallinckrodt LLC
$68
Takeda Pharmaceuticals U.S.A., Inc.
$66
Sandoz Inc.
$52
Hikma Pharmaceuticals USA
$36
Celgene Corporation
$35
Teva Pharmaceuticals USA, Inc.
$35
Flexion Therapeutics, Inc.
$34
Corcept Therapeutics
$28
Exeltis, USA Inc.
$27
IBSA Pharma Inc.
$24
Tandem Diabetes Care, Inc.
$22
Kiniksa Pharmaceuticals International, plc
$21
Organon Llc
$20
West-Ward Pharmaceuticals
$17
Egalet US Inc
$17
Novo Nordisk Inc
$17
Abbott Laboratories
$17
Merck Sharp & Dohme Corporation
$15
Boston Scientific Corporation
$14
Avion Pharmaceuticals
$11
MEDEXUS PHARMA, INC.
$11
Top 3 companies account for 31.9% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Balcoltra · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Dexcom G6 Transmitter · EVENITY · EVUSHELD · Enbrel · FORTEO · FREESTYLE LIBRE 2 · HADLIMA · HUMIRA · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · Korlym · LUPKYNIS · LYRICA · Mitigare · NONE · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PRIMARY CARE - DISEASE STATE · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tirosint · Truxima · Tyenne · Tymlos · Uloric · WATCHMAN · Wegovy · XELJANZ · Zilretta · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $491 per 100 Medicare services performed
Looking for a rheumatology in Palm Harbor?
Compare rheumatologys in the Palm Harbor area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
50
Per 100K population
5.2
County median income
$70,293
Nearest hospital
MEASE DUNEDIN HOSPITAL
5.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Nagibina is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (low-engagement, top 18%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Nagibina experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Nagibina performed 3,960 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nagibina receive payments from pharmaceutical companies?
Yes. Dr. Nagibina received a total of $25,340 from 50 companies across 1,423 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nagibina's costs compare to other rheumatologys in Palm Harbor?
Dr. Nagibina's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nagibina) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →